We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Commerzbank (CRZBY) Mulling Massive Job Cuts to Control Costs
Read MoreHide Full Article
Commerzbank AG (CRZBY - Free Report) is planning to cut in excess of 7,000 jobs and shut down about 400 branches, per Bloomberg. The company is mulling these cuts in response to the shareholder criticism over its inadequate pace of cost cutting.
The job cut and branch-closure plan have been received with skepticism within the company as some executives are of the opinion that cuts of such a scale are not feasible. Moreover, the labor representatives, who occupy half of the seats in the bank’s supervisory board, will likely object to the job cuts.
The company’s chief executive officer Martin Zielke’s track record with regard to cost cutting has not been satisfactory. In a plan announced four years ago, the company said that it would cut net 7,300 jobs but had ended up shedding only 3,600.
Notably, the company expects that the closure of branches will allow it to focus more on its digital channels. This is because more and more people are adopting digital channels as the coronavirus pandemic has resulted in a shift in consumer behavior.
A spokeswoman for the company said “We plan to disclose the details of our cost project the latest with our Q2 numbers. Currently, different options and scenarios are being discussed. No decisions have been taken.”
The company informed in February that it was working on more cost cuts as its previous cost cutting plan did not meet the investors’ expectations.
Shares of Commerzbank have gained 8.6% over the past three months compared with the industry's rally of 4.9%.
Currently, the company carries a Zacks Rank #4 (Sell).
The coronavirus pandemic has compelled a number of companies to consider job cuts as a cost-control measure. HSBC Holdings (HSBC - Free Report) has resumed its plans to cut 35,000 jobs, which had been suspended earlier. Royal Bank of Scotland is likely to slash about a quarter of the company’s jobs in its investment banking unit in the United States. Moreover, the banking arm of Mitsubishi UFJ Financial Group (MUFG - Free Report) is planning to reduce its staff by an additional 2,000 jobs by fiscal 2023.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Commerzbank (CRZBY) Mulling Massive Job Cuts to Control Costs
Commerzbank AG (CRZBY - Free Report) is planning to cut in excess of 7,000 jobs and shut down about 400 branches, per Bloomberg. The company is mulling these cuts in response to the shareholder criticism over its inadequate pace of cost cutting.
The job cut and branch-closure plan have been received with skepticism within the company as some executives are of the opinion that cuts of such a scale are not feasible. Moreover, the labor representatives, who occupy half of the seats in the bank’s supervisory board, will likely object to the job cuts.
The company’s chief executive officer Martin Zielke’s track record with regard to cost cutting has not been satisfactory. In a plan announced four years ago, the company said that it would cut net 7,300 jobs but had ended up shedding only 3,600.
Notably, the company expects that the closure of branches will allow it to focus more on its digital channels. This is because more and more people are adopting digital channels as the coronavirus pandemic has resulted in a shift in consumer behavior.
A spokeswoman for the company said “We plan to disclose the details of our cost project the latest with our Q2 numbers. Currently, different options and scenarios are being discussed. No decisions have been taken.”
The company informed in February that it was working on more cost cuts as its previous cost cutting plan did not meet the investors’ expectations.
Shares of Commerzbank have gained 8.6% over the past three months compared with the industry's rally of 4.9%.
Currently, the company carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The coronavirus pandemic has compelled a number of companies to consider job cuts as a cost-control measure. HSBC Holdings (HSBC - Free Report) has resumed its plans to cut 35,000 jobs, which had been suspended earlier. Royal Bank of Scotland is likely to slash about a quarter of the company’s jobs in its investment banking unit in the United States. Moreover, the banking arm of Mitsubishi UFJ Financial Group (MUFG - Free Report) is planning to reduce its staff by an additional 2,000 jobs by fiscal 2023.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>